Open Access
Open access
Molecules, volume 24, issue 5, pages 892

The Concept of an Ideal Antibiotic: Implications for Drug Design

Gajdács Márió 1
1
 
Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary
Publication typeJournal Article
Publication date2019-03-03
Journal: Molecules
Quartile SCImago
Q1
Quartile WOS
Q2
Impact factor4.6
ISSN14203049
Organic Chemistry
Drug Discovery
Physical and Theoretical Chemistry
Pharmaceutical Science
Molecular Medicine
Analytical Chemistry
Chemistry (miscellaneous)
Abstract
The emergence and spread of antibiotic-resistant pathogens is a major public health issue, which requires global action of an intersectoral nature. Multidrug-resistant (MDR) pathogens—especially “ESKAPE” bacteria—can withstand lethal doses of antibiotics with various chemical structures and mechanisms of action. Pharmaceutical companies are increasingly turning away from participating in the development of new antibiotics, due to the regulatory environment and the financial risks. There is an urgent need for innovation in antibiotic research, as classical discovery platforms (e.g., mining soil Streptomycetes) are no longer viable options. In addition to discovery platforms, a concept of an ideal antibiotic should be postulated, to act as a blueprint for future drugs, and to aid researchers, pharmaceutical companies, and relevant stakeholders in selecting lead compounds. Based on 150 references, the aim of this review is to summarize current advances regarding the challenges of antibiotic drug discovery and the specific attributes of an ideal antibacterial drug (a prodrug or generally reactive compound with no specific target, broad-spectrum antibacterial activity, adequate penetration through the Gram-negative cell wall, activity in biofilms and in hard-to-treat infections, accumulation in macrophages, availability for oral administration, and for use in sensitive patient groups).

Citations by journals

5
10
15
20
25
Infection and Drug Resistance
Infection and Drug Resistance, 25, 13.37%
Infection and Drug Resistance
25 publications, 13.37%
Antibiotics
Antibiotics, 17, 9.09%
Antibiotics
17 publications, 9.09%
Molecules
Molecules, 10, 5.35%
Molecules
10 publications, 5.35%
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 6, 3.21%
International Journal of Molecular Sciences
6 publications, 3.21%
Microorganisms
Microorganisms, 6, 3.21%
Microorganisms
6 publications, 3.21%
Expert Review of Anti-Infective Therapy
Expert Review of Anti-Infective Therapy, 5, 2.67%
Expert Review of Anti-Infective Therapy
5 publications, 2.67%
Pharmaceuticals
Pharmaceuticals, 4, 2.14%
Pharmaceuticals
4 publications, 2.14%
Pathogens
Pathogens, 3, 1.6%
Pathogens
3 publications, 1.6%
Future Microbiology
Future Microbiology, 2, 1.07%
Future Microbiology
2 publications, 1.07%
Microbial Drug Resistance
Microbial Drug Resistance, 2, 1.07%
Microbial Drug Resistance
2 publications, 1.07%
Diseases
Diseases, 2, 1.07%
Diseases
2 publications, 1.07%
Medicina
Medicina, 2, 1.07%
Medicina
2 publications, 1.07%
Pharmaceutics
Pharmaceutics, 2, 1.07%
Pharmaceutics
2 publications, 1.07%
Dentistry Journal
Dentistry Journal, 2, 1.07%
Dentistry Journal
2 publications, 1.07%
Life
Life, 2, 1.07%
Life
2 publications, 1.07%
Frontiers in Immunology
Frontiers in Immunology, 2, 1.07%
Frontiers in Immunology
2 publications, 1.07%
Frontiers in Microbiology
Frontiers in Microbiology, 2, 1.07%
Frontiers in Microbiology
2 publications, 1.07%
International Journal of Peptide Research and Therapeutics
International Journal of Peptide Research and Therapeutics, 2, 1.07%
International Journal of Peptide Research and Therapeutics
2 publications, 1.07%
BMC Infectious Diseases
BMC Infectious Diseases, 2, 1.07%
BMC Infectious Diseases
2 publications, 1.07%
Current Microbiology
Current Microbiology, 2, 1.07%
Current Microbiology
2 publications, 1.07%
Bioorganic and Medicinal Chemistry Letters
Bioorganic and Medicinal Chemistry Letters, 2, 1.07%
Bioorganic and Medicinal Chemistry Letters
2 publications, 1.07%
Microbial Pathogenesis
Microbial Pathogenesis, 2, 1.07%
Microbial Pathogenesis
2 publications, 1.07%
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, 2, 1.07%
Journal of Antimicrobial Chemotherapy
2 publications, 1.07%
Expert Opinion on Drug Discovery
Expert Opinion on Drug Discovery, 2, 1.07%
Expert Opinion on Drug Discovery
2 publications, 1.07%
Patient Preference and Adherence
Patient Preference and Adherence, 2, 1.07%
Patient Preference and Adherence
2 publications, 1.07%
Journal of wound care, 2, 1.07%
Journal of wound care
2 publications, 1.07%
Evidence-based Complementary and Alternative Medicine
Evidence-based Complementary and Alternative Medicine, 1, 0.53%
Evidence-based Complementary and Alternative Medicine
1 publication, 0.53%
Journal of Controlled Release
Journal of Controlled Release, 1, 0.53%
Journal of Controlled Release
1 publication, 0.53%
Current Topics in Medicinal Chemistry
Current Topics in Medicinal Chemistry, 1, 0.53%
Current Topics in Medicinal Chemistry
1 publication, 0.53%
5
10
15
20
25

Citations by publishers

10
20
30
40
50
60
70
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 62, 33.16%
Multidisciplinary Digital Publishing Institute (MDPI)
62 publications, 33.16%
Dove Medical Press
Dove Medical Press, 29, 15.51%
Dove Medical Press
29 publications, 15.51%
Springer Nature
Springer Nature, 18, 9.63%
Springer Nature
18 publications, 9.63%
Elsevier
Elsevier, 13, 6.95%
Elsevier
13 publications, 6.95%
Taylor & Francis
Taylor & Francis, 10, 5.35%
Taylor & Francis
10 publications, 5.35%
Frontiers Media S.A.
Frontiers Media S.A., 6, 3.21%
Frontiers Media S.A.
6 publications, 3.21%
Hindawi Limited
Hindawi Limited, 4, 2.14%
Hindawi Limited
4 publications, 2.14%
Future Medicine
Future Medicine, 3, 1.6%
Future Medicine
3 publications, 1.6%
American Chemical Society (ACS)
American Chemical Society (ACS), 3, 1.6%
American Chemical Society (ACS)
3 publications, 1.6%
American Society for Microbiology
American Society for Microbiology, 3, 1.6%
American Society for Microbiology
3 publications, 1.6%
Wiley
Wiley, 3, 1.6%
Wiley
3 publications, 1.6%
Bentham Science
Bentham Science, 2, 1.07%
Bentham Science
2 publications, 1.07%
Mary Ann Liebert
Mary Ann Liebert, 2, 1.07%
Mary Ann Liebert
2 publications, 1.07%
Oxford University Press
Oxford University Press, 2, 1.07%
Oxford University Press
2 publications, 1.07%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 2, 1.07%
Royal Society of Chemistry (RSC)
2 publications, 1.07%
Mark Allen Group, 2, 1.07%
Mark Allen Group
2 publications, 1.07%
IGI Global
IGI Global, 1, 0.53%
IGI Global
1 publication, 0.53%
Akademiai Kiado
Akademiai Kiado, 1, 0.53%
Akademiai Kiado
1 publication, 0.53%
Wolters Kluwer Health
Wolters Kluwer Health, 1, 0.53%
Wolters Kluwer Health
1 publication, 0.53%
University of Szeged, 1, 0.53%
University of Szeged
1 publication, 0.53%
Slovenian Medical Society, 1, 0.53%
Slovenian Medical Society
1 publication, 0.53%
Proceedings of the National Academy of Sciences (PNAS)
Proceedings of the National Academy of Sciences (PNAS), 1, 0.53%
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.53%
Remedium, Ltd.
Remedium, Ltd., 1, 0.53%
Remedium, Ltd.
1 publication, 0.53%
Spandidos Publications
Spandidos Publications, 1, 0.53%
Spandidos Publications
1 publication, 0.53%
Xi'an Jiaotong University, 1, 0.53%
Xi'an Jiaotong University
1 publication, 0.53%
Oriental Scientific Publishing Company, 1, 0.53%
Oriental Scientific Publishing Company
1 publication, 0.53%
10
20
30
40
50
60
70
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Gajdács M. The Concept of an Ideal Antibiotic: Implications for Drug Design // Molecules. 2019. Vol. 24. No. 5. p. 892.
GOST all authors (up to 50) Copy
Gajdács M. The Concept of an Ideal Antibiotic: Implications for Drug Design // Molecules. 2019. Vol. 24. No. 5. p. 892.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.3390/molecules24050892
UR - https://doi.org/10.3390%2Fmolecules24050892
TI - The Concept of an Ideal Antibiotic: Implications for Drug Design
T2 - Molecules
AU - Gajdács, Márió
PY - 2019
DA - 2019/03/03 00:00:00
PB - Multidisciplinary Digital Publishing Institute (MDPI)
SP - 892
IS - 5
VL - 24
PMID - 30832456
SN - 1420-3049
ER -
BibTex |
Cite this
BibTex Copy
@article{2019_Gajdács,
author = {Márió Gajdács},
title = {The Concept of an Ideal Antibiotic: Implications for Drug Design},
journal = {Molecules},
year = {2019},
volume = {24},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
month = {mar},
url = {https://doi.org/10.3390%2Fmolecules24050892},
number = {5},
pages = {892},
doi = {10.3390/molecules24050892}
}
MLA
Cite this
MLA Copy
Gajdács, Márió. “The Concept of an Ideal Antibiotic: Implications for Drug Design.” Molecules, vol. 24, no. 5, Mar. 2019, p. 892. https://doi.org/10.3390%2Fmolecules24050892.
Found error?